*Aurinia Pharmaceuticals Inc.

Changing the course of autoimmune disease

Inspired by patients. Driven to make an impact.

Latest News

June 6, 2022 • 4:05pm EDT

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read Press Release View All News

June 3, 2022 • 7:05am EDT

Aurinia Presents Data Demonstrating LUPKYNIS® (voclosporin) is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations

Read Press Release View All News

May 20, 2022 • 12:07pm EDT

Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress

Read Press Release View All News